Nedal

Quick links to important sections

Nedal

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nedal

Quick Facts: Nedal (Nebivolol)

Property Description
Active Ingredient Nebivolol (INN)
Form Oral tablet, film-coated
Pharmacological Class Beta Blocker (eta-Adrenergic Antagonist)
General Purpose Managing conditions of the circulatory system
Origin Synthetic small molecule

What Type of Medicine is Nedal?

Nedal is a registered brand name for a prescription-only medicine whose active ingredient is the synthetic small molecule Nebivolol, typically formulated as Nebivolol hydrochloride. It is classified within the pharmacological class of beta blockers (eta-adrenergic antagonists), which are widely used as Antihypertensive Agents to manage cardiovascular conditions. Nebivolol is distinguished in clinical practice as a third-generation agent with high cardioselectivity at typical dosing. This means its action is strongly focused on specific receptors that help regulate the heart's function in adults.

Nebivolol’s Dual Action and General Benefit

The general therapeutic purpose of Nedal is to stabilize blood pressure and reduce the heart's workload through a distinctive dual mechanism of action. While its primary role is eta1-antagonism, Nebivolol is unique among its class for possessing a secondary vasodilatory property that promotes the release of nitric oxide (NO) within the walls of blood vessels. This latter mechanism causes the blood vessels to relax and widen, thus lowering peripheral vascular resistance. The combination of slowing the heart rate and relaxing the vessels provides a comprehensive antihypertensive benefit that helps reduce the strain on the circulatory system and promotes healthy blood flow.

Nedal’s Composition and Pharmaceutical Form

The active ingredient, Nebivolol, is chemically defined as a racemic mixture, meaning it is composed of two distinct enantiomers, the d-enantiomer and the l-enantiomer, which work together to produce the drug's full therapeutic profile. As a pharmaceutical product, Nedal is a single-ingredient product formulated as an oral tablet that is film-coated. This solid dosage form is designed for administration via the oral route, relying on pharmaceutical excipients for stable delivery of the active substance to meet the chronic cardiovascular needs of adult patients.

What side effects are possible with Nedal?

The official safety profile of Nedal (Nebivolol) is established by government regulatory bodies, which classify potential adverse reactions based on their frequency of occurrence during clinical studies. These classifications group effects by the physiological system involved.

Frequency-Classified Adverse Reactions

Adverse reactions classified as Common (occurring in 1% to 10% of patients) typically involve the nervous system (headache, dizziness, paraesthesia) and general disorders (fatigue, edema). Gastrointestinal effects often reported at this frequency include nausea, diarrhea, and constipation.

Effects listed as Uncommon (0.1% to 1%) may include bradycardia (slowed heart rate), hypotension, heart failure aggravation, nightmares, depression, and impotence. Very Rare effects (less than 0.01%) include syncope and the aggravation of psoriasis.

Serious Safety Considerations

The most significant safety warning is related to abrupt discontinuation of therapy; sudden withdrawal may lead to severe cardiac events, including the exacerbation of angina, myocardial infarction, and ventricular arrhythmias. The use of Nedal is contraindicated (must not be used) in patients with severe pre-existing cardiac conditions such as severe bradycardia, second or third-degree heart block, cardiogenic shock, and decompensated heart failure. Severe hepatic impairment is also a contraindication.

Population-Specific Safety Notes

Official labeling addresses specific populations, noting that Nebivolol may mask certain symptoms of hypoglycemia (specifically a fast heartbeat) in diabetic patients. For individuals with severe renal impairment, a reduced initial dose is required due to decreased drug clearance. Safety and efficacy for the pediatric population have not been established in regulatory documents.

Overdose and Emergency Response

The official regulatory documentation for Nedal defines overdose by the severe exaggeration of the drug’s core physiological effects. Overdose may present with critical manifestations involving the cardiovascular and respiratory systems.

System Affected Documented Manifestations
Cardiovascular Bradycardia (abnormally slow heart rate), severe Hypotension, Acute Heart Failure, and advanced Heart Block (second or third degree).
Systemic/CNS Dizziness, fatigue, vomiting, and Hypoglycemia (low blood glucose).
Respiratory Bronchospasm (constriction of airways).

Overdose is classified as a potentially life-threatening event, demanding immediate action. Seek emergency medical attention right away for any suspected overdose. Official documents require contacting a Poison Control Center for specialized guidance; emergency services must be called immediately if the person is severely struggling to breathe, collapses, or is unconscious. No specific antidote is known for Nebivolol overdose. Treatment focuses entirely on supportive management, utilizing methods listed in regulatory documents such as intravenous atropine for bradycardia, vasopressors and IV fluids for hypotension, or bronchodilator therapy for bronchospasm. Continuous vital sign and ECG monitoring are required. Furthermore, official guidance notes that hypoglycemia is a particular concern in pediatric patients.

Therapeutic Uses of Nedal

Main uses of Nedal

Nedal contains the active substance nebivolol, which belongs to the class of medications known as beta-blockers. It is primarily used for the management of cardiovascular conditions involving the heart and blood vessels.

Essential Hypertension

Nedal is used to treat essential hypertension, commonly known as high blood pressure. By helping to relax and widen the blood vessels, the medication assists in lowering blood pressure levels. This reduction is important because persistent high blood pressure increases the workload on the heart and can lead to long-term damage to the arteries.

Chronic Heart Failure

This medication is also used as part of a standard treatment regimen for stable chronic heart failure. It is often prescribed for patients, particularly those aged 70 and older, alongside other heart failure therapies. In this context, the medication helps to improve heart function by making the heartbeat more efficient.

Benefits and Mechanism of Action

Nebivolol differs from some other beta-blockers due to its dual mechanism of action, which provides specific therapeutic benefits:

  • Heart Rate Regulation: It prevents an abnormally fast heart rate, allowing the heart to pump more effectively.
  • Vasodilation: It stimulates the release of nitric oxide in the inner lining of the blood vessels. This action helps the blood vessels to dilate, which improves blood flow and further assists in reducing blood pressure.
  • Selective Action: At standard therapeutic doses, the medication primarily targets the heart's receptors, which helps minimize effects on other systems, such as the respiratory tract.

In patients with heart failure, these actions contribute to a reduction in cardiovascular-related hospitalizations and help manage the symptoms associated with weakened heart function.

Eligibility and Restrictions for Use

Who Can and Cannot Use Nedal?

Nedal (Nebivolol) is officially approved for use in adults to manage essential hypertension. It is also indicated for adults aged 70 years and older who have stable mild and moderate chronic heart failure. Use in children and adolescents (under 18 years) is not established and not recommended, as safety and efficacy have not been determined in the pediatric population.


Absolute Contraindications

The medicine is contraindicated (must not be used) in several populations, primarily due to unstable physiological states. These absolute restrictions include severe bradycardia, second or third-degree heart block, cardiogenic shock, and decompensated cardiac failure. Use is also prohibited in patients with severe hepatic impairment and known hypersensitivity to the active ingredient or any excipients.


Restricted and Conditional Use

Nedal is subject to further restrictions in specific populations. Use is not recommended during pregnancy or lactation. Patients with severe renal impairment or moderate hepatic impairment require conditional use with close monitoring. Caution is explicitly advised for those with comorbidities like bronchospastic diseases or diabetes, as the medicine may mask certain clinical signs.

What should I know about interactions with other medicines?

Nedal, like all prescription medicines, has the potential to interact with other drugs, substances, and certain supplements. These interactions can alter how effectively Nedal works or increase the risk of side effects.

Potential Drug Interactions

Interacting Product Category Clinical Significance and Effect
Other antihypertensives Additive effects may cause excessive lowering of blood pressure, leading to dizziness or fainting.
Calcium Channel Blockers Co-administration may enhance the effects on heart rate and contractility, increasing the risk of bradycardia (slow heart rate) or heart block.
Digitalis Glycosides May lead to an excessive reduction in heart rate. Close monitoring of heart function is typically required.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) May potentially reduce the blood pressure-lowering effect of Nedal.
Certain Antiarrhythmics Concomitant use with other agents affecting cardiac rhythm may increase the risk of arrhythmias or conduction issues.

General Precautionary Notes

This medication's effects may be influenced by substances that interact with liver enzyme systems responsible for drug clearance. Patients should inform their healthcare provider of all prescription and non-prescription medicines, vitamins, and herbal products currently being used. The combination with alcohol may have an additive effect in lowering blood pressure, which can result in dizziness or lightheadedness. Do not stop or start any other medication without first consulting a healthcare professional.

Mechanism of Action

How Nedal Works

Nedal (Nebivolol) exerts its physiological effects through a distinct dual mechanism that simultaneously acts on the heart and the blood vessels, leading to a coordinated physiological modulation of the circulatory system. This mechanism is governed by the drug's composition as a racemic mixture, which facilitates two different molecular interactions resulting in synergistic effects.


The Cardiac Brake: Selective beta1-Receptor Blockade

The primary action involves the selective targeting and antagonism of beta1-adrenergic receptors (beta1-AR) in the heart. By suppressing the binding of stress hormones like Norepinephrine, this mechanism limits the rate and force of heart muscle contraction. The physiological consequence is a state of negative chronotropy (slowing of the heart rate) and negative inotropy (reduced contractile force), which collectively reduces cardiac oxygen consumption and intrinsic mechanical stress.


Vascular Widening: beta3-Agonism and Nitric Oxide Release

The drug's secondary action involves stimulating the release of Nitric Oxide (NO) from the inner lining of blood vessels. This effect is mediated by the agonism of beta3-adrenergic receptors (beta3-AR), which activates the eNOS enzyme to synthesize NO. The resulting NO acts as a signaling molecule to relax the surrounding arterial smooth muscle, leading to systemic vasodilation and a subsequent reduction in peripheral vascular resistance.

Dosage and Administration Information

Nedal is an oral medicine administered via a film-coated tablet for the long-term management of chronic cardiovascular conditions. The administration protocol is based on standard clinical protocols, emphasizing a gradual dose adjustment and consistent daily timing to ensure stable use.


Administration Protocol and Dosing Schedule

Use Condition Starting Dose Titration Schedule Maximum Daily Dose
Essential Hypertension 5 mg once daily Dose adjustments may occur every two weeks 40 mg once daily
Stable Chronic Heart Failure (CHF) 1.25 mg once daily Dose is gradually doubled every 1–2 weeks 10 mg once daily

The tablet must be taken once daily at the same time each day, regardless of food consumption. The initial doses, particularly for Chronic Heart Failure, are very low and are slowly increased over several weeks, a process that requires the supervision of a physician experienced in managing the condition. The tablet may be divided to achieve the necessary low doses or fractional adjustments.

Special Population and Discontinuation Rules

Standard guidelines detail modified starting doses for certain populations. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) or moderate hepatic impairment should begin with 2.5 mg once daily. Similarly, a 2.5 mg starting dose is commonly applied in older adults (over 65) beginning treatment for CHF.

If a daily dose is missed, the instruction is to skip that dose entirely and take the next one at the regular time; the dose should not be doubled. Treatment with Nedal must not be stopped abruptly; instead, the dose should be gradually reduced over a period of 1 to 2 weeks before full discontinuation, a necessary procedural step for safe therapy cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nedal (Nebivolol)

The clinical background for Nedal is based on official research evidence, including randomized controlled trials (RCTs) and long-term outcome studies, which are used by health authorities to support the medicine's approved uses. This overview summarizes the structure of this research without providing clinical advice or recommendations.


Evidence for Essential Hypertension (High Blood Pressure)

Nedal was studied in the context of essential hypertension through multiple randomized controlled trials (RCTs) and meta-analyses. The research primarily examined changes in objective measurements of blood pressure, specifically systolic and diastolic pressure (SBP and DBP), in adult patients.

Studies report patterns where the measured blood pressure values were lower in the group receiving Nedal compared to the group receiving an inactive placebo. Comparative trials examined the difference in blood pressure changes when Nedal was evaluated against other agents. However, the research focused heavily on surrogate outcomes (blood pressure readings) rather than consistently tracking long-term, hard clinical events against placebo.


Evidence for Stable Chronic Heart Failure

Research for Nedal in stable chronic heart failure (CHF) was evaluated in a large, long-term, placebo-controlled outcome trial. This research was specifically designed to include elderly patients (aged 70 years and older) and monitored a key combined outcome that included measurements of all-cause mortality and hospitalizations for cardiovascular events.

The core study reported a difference in the rate of the primary composite outcome when compared to placebo. However, research describes that findings were mixed when examining all-cause mortality as an isolated outcome measure in the overall study population. The definitive evidence related to mortality and hospitalization is limited to individuals aged 70 years and older; comparable outcome data for younger adult patients with heart failure are still emerging.


Evidence in Special Study Populations and Uncertainties

Nedal was studied in certain special populations. The primary evidence for chronic heart failure was generated in elderly patients, and studies for hypertension evaluated African American patients. Evidence highlights that in hypertension, research has explored the influence on vascular markers like endothelial function. However, these are not hard clinical outcomes, and comparative evidence in this area has shown findings were mixed and certainty remains low.

Key Studies & References The Efficacy and Tolerability of Nebivolol in Hypertensive African American Patients

Frequently Asked Questions (FAQ)

Common questions about Nedal (FAQ)


Q: Why does Nedal need to be taken consistently?

A: Taking Nedal at the same time each day is a requirement in official use guidelines for the long-term management of chronic conditions. This consistent daily timing helps to maintain stable concentrations of the medicine in the body. Stable concentrations are linked to the drug's intended action in managing chronic conditions, as indicated in regulatory documents.

Q: Are there any ongoing clinical trials related to Nedal?

A: The official documentation used for the medicine's approval is based on completed clinical trials that were utilized by regulatory bodies in their determination of the medicine's approved uses. Information about new, ongoing research or clinical trials is maintained by governmental registries that track current investigations into the medicine's potential uses and effects.

Q: Why do official documents describe Nedal's use condition so carefully?

A: Official documents describe use conditions carefully because the drug's approved uses are restricted to the exact conditions and patient populations that were studied in clinical trials. This careful description reflects the specific indications and patient groups for which the drug's safety and benefit were demonstrated in clinical trials and accepted by regulators.

Q: Can Nedal be crushed or split if it's hard to swallow?

A: Official administration instructions confirm that the Nedal tablet may be divided, but this instruction is primarily provided to help achieve specific low doses or fractional adjustments during the initial titration phase. Any specific guidance on swallowing the tablet should be directed to a healthcare professional.

Q: What are the warning signs of a serious interaction involving Nedal?

A: Potential serious interactions or excessive lowering of blood pressure may lead to symptoms such as feeling dizzy, lightheaded, or faint. Regulatory warnings describe that symptoms such as feeling faint or changes in pulse are important to discuss with a healthcare professional.

Q: What is the typical expectation for follow-up appointments when taking Nedal?

A: Official documentation indicates that Nedal therapy requires regular medical monitoring. This is particularly true during the initial period, known as dose titration, where the dosage may be adjusted every one to two weeks. Regular follow-up allows a healthcare professional to monitor blood pressure and heart rate.

Q: Is Nedal available in different strengths?

A: Yes, Nedal is supplied as an oral, film-coated tablet in multiple strengths to allow for the appropriate management of chronic cardiovascular conditions. The officially listed strengths typically include 2.5 mg, 5 mg, 10 mg, and 20 mg tablets.

Q: How long does it usually take for Nedal to start working?

A: After taking a dose, the maximum concentration of Nedal in the bloodstream is usually reached within 1.5 to 4 hours. However, for chronic conditions, the full therapeutic effect on blood pressure stabilization may not become fully apparent until several weeks after therapy has started.

Q: Can Nedal affect my ability to drive or operate machinery?

A: Official patient information includes a general precaution that the medicine may affect coordination, reaction time, or judgment, often due to side effects like dizziness or fatigue. Regulatory patient information includes precautions regarding driving or operating machinery until an individual is aware of how the medicine may affect their coordination or reaction time.

Q: Is Nedal habit-forming or addictive?

A: Nedal is officially designated as not being a controlled substance and is not classified as an addictive medicine. The official regulatory warning relates to the necessity of gradually reducing the dose before stopping therapy to avoid severe cardiac withdrawal events.

Q: Does Nedal cause weight gain or weight loss?

A: Official lists of adverse reactions, based on clinical studies, include reports of unusual changes in body weight, encompassing both weight gain and weight loss. These changes are generally classified as uncommon effects.

Q: What is the shelf life of Nedal tablets?

A: The official product labeling specifies that the tablets have a defined shelf life when stored correctly according to pharmaceutical standards. This shelf life may be up to 24 months from the date of manufacture.

Q: Does Nedal have a generic version available?

A: Yes, the active ingredient in Nedal, Nebivolol, has received approval for generic versions by major regulatory bodies like the FDA. This indicates that chemically equivalent versions of the medicine are commercially available.

Q: Does taking Nedal affect cholesterol levels?

A: Official warnings describe that Nedal, similar to other medicines in its class, may alter serum lipid profiles, which include cholesterol and triglyceride levels. Official documentation notes that the need for monitoring of lipid levels in patients with pre-existing high levels is an area to be considered.

Q: Why do some people feel restless when they take Nedal?

A: The official list of adverse reactions includes reports of psychiatric effects such as nervousness and anxiety. These effects, though uncommon, are related to the central nervous system and may be experienced by some individuals as feelings of restlessness.

Q: Is Nedal used in emergency situations?

A: Nedal is officially indicated for the long-term management of chronic cardiovascular conditions, requiring a slow, gradual dose adjustment. Its use is specifically prohibited (contraindicated) in acute, unstable emergency situations such as cardiogenic shock and decompensated heart failure.

Q: Does smoking affect how Nedal works?

A: Official patient information notes that tobacco use is an external factor that should be discussed with a healthcare provider, as it could potentially interact with the medicine's mechanism or affect how effectively the body processes the drug.

How should Nedal be stored and disposed of?

How to Store and Dispose of Nedal?

This section describes the officially documented storage and disposal requirements for Nedal (nebivolol) tablets.


Official Storage Requirements

Nedal must be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F), with storage below 25 C required in some regions. The medicine should be protected from excess heat and moisture and must remain in its original container, which should be kept tightly closed. A mandatory safety requirement is to store Nedal out of the sight and reach of children.

Disposal Instructions

Unused or expired Nedal must be disposed of according to local regulations. The preferred method is using a community drug take-back program. If not available, the tablets can be discarded in the household trash after mixing them with an undesirable substance, such as dirt or used coffee grounds, and sealing the mixture in a container. Nedal should not be flushed down a toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nedal found in:

A-Z Index: